These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 29118924)
21. Differential expression of CD97 on human lymphocyte subsets and limited effect of CD97 antibodies on allogeneic T-cell stimulation. Kop EN; Matmati M; Pouwels W; Leclercq G; Tak PP; Hamann J Immunol Lett; 2009 Apr; 123(2):160-8. PubMed ID: 19428565 [TBL] [Abstract][Full Text] [Related]
22. Analysis of CD97 expression and manipulation: antibody treatment but not gene targeting curtails granulocyte migration. Veninga H; Becker S; Hoek RM; Wobus M; Wandel E; van der Kaa J; van der Valk M; de Vos AF; Haase H; Owens B; van der Poll T; van Lier RA; Verbeek JS; Aust G; Hamann J J Immunol; 2008 Nov; 181(9):6574-83. PubMed ID: 18941248 [TBL] [Abstract][Full Text] [Related]
23. Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. Kwakkenbos MJ; Pouwels W; Matmati M; Stacey M; Lin HH; Gordon S; van Lier RA; Hamann J J Leukoc Biol; 2005 Jan; 77(1):112-9. PubMed ID: 15498814 [TBL] [Abstract][Full Text] [Related]
24. To Detach, Migrate, Adhere, and Metastasize: CD97/ Aust G; Zheng L; Quaas M Cells; 2022 May; 11(9):. PubMed ID: 35563846 [TBL] [Abstract][Full Text] [Related]
25. PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839). Shien T; Doihara H; Hara H; Takahashi H; Yoshitomi S; Taira N; Ishibe Y; Teramoto J; Aoe M; Shimizu N Breast Cancer; 2004; 11(4):367-73. PubMed ID: 15604992 [TBL] [Abstract][Full Text] [Related]
26. CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent. Liu D; Li C; Trojanowicz B; Li X; Shi D; Zhan C; Wang Z; Chen L Gastric Cancer; 2016 Jul; 19(3):754-66. PubMed ID: 26233326 [TBL] [Abstract][Full Text] [Related]
27. Dual role of the adhesion G-protein coupled receptor ADRGE5/CD97 in glioblastoma invasion and proliferation. Slepak TI; Guyot M; Walters W; Eichberg DG; Ivan ME J Biol Chem; 2023 Sep; 299(9):105105. PubMed ID: 37517698 [TBL] [Abstract][Full Text] [Related]
28. MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells. Park GB; Kim D Neoplasia; 2019 Feb; 21(2):206-215. PubMed ID: 30622051 [TBL] [Abstract][Full Text] [Related]
29. Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer. He Z; Wu H; Jiao Y; Zheng J Oncol Lett; 2015 Feb; 9(2):793-797. PubMed ID: 25624904 [TBL] [Abstract][Full Text] [Related]
31. CD97 in leukocyte trafficking. Hamann J; Veninga H; de Groot DM; Visser L; Hofstra CL; Tak PP; Laman JD; Boots AM; van Eenennaam H Adv Exp Med Biol; 2010; 706():128-37. PubMed ID: 21618832 [TBL] [Abstract][Full Text] [Related]
32. Short-hairpin RNA-mediated MTA2 silencing inhibits human breast cancer cell line MDA-MB231 proliferation and metastasis. Lu J; Jin ML Asian Pac J Cancer Prev; 2014; 15(14):5577-82. PubMed ID: 25081667 [TBL] [Abstract][Full Text] [Related]
33. EGF induces epithelial-mesenchymal transition through phospho-Smad2/3-Snail signaling pathway in breast cancer cells. Kim J; Kong J; Chang H; Kim H; Kim A Oncotarget; 2016 Dec; 7(51):85021-85032. PubMed ID: 27829223 [TBL] [Abstract][Full Text] [Related]
34. Molecular cloning and characterization of mouse CD97. Hamann J; van Zeventer C; Bijl A; Molenaar C; Tesselaar K; van Lier RA Int Immunol; 2000 Apr; 12(4):439-48. PubMed ID: 10744645 [TBL] [Abstract][Full Text] [Related]
35. The Adhesion GPCR CD97/ADGRE5 inhibits apoptosis. Hsiao CC; Keysselt K; Chen HY; Sittig D; Hamann J; Lin HH; Aust G Int J Biochem Cell Biol; 2015 Aug; 65():197-208. PubMed ID: 26071181 [TBL] [Abstract][Full Text] [Related]
36. Morin, a flavonoid from Moraceae, suppresses growth and invasion of the highly metastatic breast cancer cell line MDA-MB‑231 partly through suppression of the Akt pathway. Jin H; Lee WS; Eun SY; Jung JH; Park HS; Kim G; Choi YH; Ryu CH; Jung JM; Hong SC; Shin SC; Kim HJ Int J Oncol; 2014 Oct; 45(4):1629-37. PubMed ID: 24993541 [TBL] [Abstract][Full Text] [Related]
37. CD97 Promotes Tumor Aggressiveness Through the Traditional G Protein-Coupled Receptor-Mediated Signaling in Hepatocellular Carcinoma. Yin Y; Xu X; Tang J; Zhang W; Zhangyuan G; Ji J; Deng L; Lu S; Zhuo H; Sun B Hepatology; 2018 Nov; 68(5):1865-1878. PubMed ID: 29704239 [TBL] [Abstract][Full Text] [Related]
38. Identification of the epidermal growth factor-TM7 receptor EMR2 and its ligand dermatan sulfate in rheumatoid synovial tissue. Kop EN; Kwakkenbos MJ; Teske GJ; Kraan MC; Smeets TJ; Stacey M; Lin HH; Tak PP; Hamann J Arthritis Rheum; 2005 Feb; 52(2):442-50. PubMed ID: 15693006 [TBL] [Abstract][Full Text] [Related]
39. Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Qian YM; Haino M; Kelly K; Song WC Immunology; 1999 Oct; 98(2):303-11. PubMed ID: 10540231 [TBL] [Abstract][Full Text] [Related]
40. CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Aust G; Steinert M; Schütz A; Boltze C; Wahlbuhl M; Hamann J; Wobus M Am J Clin Pathol; 2002 Nov; 118(5):699-707. PubMed ID: 12428789 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]